ReNeuron Group Limited
("ReNeuron" or the "Company")

Strategic collaboration with Swansea University
ReNeuron establishes new premises at Swansea University for further development of CustomEX™

London, UK, 2 March 2026 – ReNeuron Group Limited, a biotechnology company harnessing the natural biology of exosomes to develop next-generation drug delivery systems, announces a strategic collaboration with Swansea University for a ReNeuron sponsored research project focused on the development of CustomEX™ as a next-generation drug delivery system.

As part of the collaboration, ReNeuron will establish a new operational premises at the Institute of Life Science located at Swansea University. The re-establishment of operations in South Wales supports ReNeuron's long-term growth strategy and ongoing commitment to R&D activity and biotech growth in the region, as well as increased commercial activity. This collaboration will also support ongoing relationships to leverage CustomEX™ as a new therapeutic pipeline.

The collaboration with Swansea University combines ReNeuron's expertise in exosome biology and manufacturing and access to Swansea University's infrastructure, such as specialist labs, instrumentation, and academic expertise, to carry out this work. Funding for the study includes one full-time research associate at Swansea University, alongside the support of Professors Steve Conlan and Deya Gonzalez, Reproductive Biology and Gynaecological oncology research group, who will act as lead academics from Swansea University.

The aim of the study is to generate crucial insights into how exosome origin influences tropism and functionality, ultimately demonstrating the platform's ability to deliver functional therapeutic cargo to specific target cells. The project will build on prior proof-of-concept data and ongoing translational research centred around the ability of CustomEX™ to traverse complex biological barriers and deliver therapeutic modalities to hard-to-reach organs and cell types. Key areas of investigation will include the characterisation of Critical Quality Attributes (CQAs), cargo loading methods, and the exploration of cellular tropism.

ReNeuron's CustomEX™ platform comprises a portfolio of proprietary, stem cell-derived exosome producer cell lines that enable the consistent and scalable manufacture of exosomes with unique biological properties, including preferential miRNA loading and highly specific tissue and cellular targeting.

Randolph Corteling, Managing Director and Chief Scientific Officer of ReNeuron, commented: *"We are delighted to be back working in South Wales with Swansea University as we look to increase commercial activity and progress our commitments to R&D. Collaboration with Swansea University provides us with the infrastructure and support to leverage our CustomEX™ platform as a new therapeutic pipeline as well as enabling us to grow and progress the business in line with our strategic goals."*

Enquiries:

ReNeuron Group Limited **Via Walbrook PR**
Iain Ross, Chairman
Randolph Corteling, Managing Director & Chief Scientific Officer

Walbrook PR (Media & Investor Relations) Tel: +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 or Mob: +44 (0)7980 541 893



About ReNeuron

At ReNeuron, we are advancing precision medicine through the development of our CustomEX™ platform - a proprietary, stem cell-derived, exosome-based drug delivery platform with customisable cellular targeting capabilities for the delivery of complex therapeutic modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissue targets and payloads, leading to improved therapeutic outcomes and reduced off-target effects. ReNeuron's technology offers a delivery mechanism for a variety of payloads, such as siRNA, mRNA, proteins and small molecules.

In addition, our conditionally immortalised induced pluripotent stem cell (CI-iPSC) platform, allows the Company to make allogeneic cell lines of choice and has the potential to produce exosomes with discrete, tissue specific targeting capabilities.

Our leadership team and Board of Directors bring over 50 years of combined experience in the life sciences sector, having successfully guided multiple innovative platforms and medicines from development through to commercialisation.

For further information visit www.reneuron.com.